85 results
6-K
EX-99.4
AMYT
Amryt Pharma Plc
5 May 21
Agreement and Plan of Merger
5:19pm
to publish and disclose its identity and ownership of the Subject Securities and the nature of its obligations under this Agreement in any announcement … of the Subject Securities, free and clear of any liens, adverse claims, charges or other encumbrances of any nature whatsoever (other than pursuant to (x
F-1
EX-2.2
AMYT
Amryt Pharma Plc
23 Jun 20
Registration statement (foreign)
5:21pm
proprietary knowledge and information, and all rights and forms of protection of a similar nature or having equivalent or similar effect to any of these which … rights, encumbrances and other limitations of any nature whatsoever, to the Buyer with economic effect as of the Closing Date. The Shares are sold
6-K
EX-99.3
AMYT
Amryt Pharma Plc
5 May 21
Agreement and Plan of Merger
5:19pm
of the Subject Securities and the nature of its obligations under this Agreement in any announcement or disclosure required by Applicable Law or the SEC … claims, charges or other encumbrances of any nature whatsoever (other than pursuant to (x) restrictions on transfer under applicable securities laws
6-K
EX-99.2
AMYT
Amryt Pharma Plc
5 May 21
Agreement and Plan of Merger
5:19pm
to publish and disclose its identity and ownership of the Subject Securities and the nature of its obligations under this Agreement in any announcement … Securities, free and clear of any liens, adverse claims, charges or other encumbrances of any nature whatsoever (other than pursuant to (x) restrictions
6-K
EX-99.1
4k2h4pg04p68e7bvf
23 Aug 21
Options Granted to Non-Executive Directors
8:16am
424B3
972dd0 4ldti6619
28 Feb 22
Prospectus supplement
12:02pm
424B3
til4qh 9m9qor5
28 Feb 22
Prospectus supplement
12:01pm
F-1
EX-10.11.1
77deop5pa08n1jufky
23 Jun 20
Registration statement (foreign)
5:21pm
424B3
32kn7x7
9 Mar 22
Prospectus supplement
9:25am
6-K
EX-99.1
1k7pdjz8uormup8jw26n
28 Feb 22
Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA
12:00pm
DRS/A
EX-10.11
ses9qb
11 May 20
Draft registration statement (amended)
12:00am
424B3
7b9kfdi
9 Mar 22
Prospectus supplement
9:26am
6-K
EX-99.1
3e677n8a7z9
9 Mar 22
Amryt Announces 22% growth in FY 2021 Revenues to $222.5M
9:23am
F-1
EX-10.12.1
xi0ujwl4f0o6idi1r
23 Jun 20
Registration statement (foreign)
5:21pm
DRS/A
EX-10.12
20c1hjomfsxc4dpk
11 May 20
Draft registration statement (amended)
12:00am
6-K
EX-99.1
4qrp hr635vqydukj
4 May 22
Amryt Reports Record Q1 2022 Results
7:43am
424B3
kcjgky 3ym9i8pek
4 May 22
Prospectus supplement
7:45am
F-1
EX-2.1
yekbd
23 Jun 20
Registration statement (foreign)
5:21pm
DRSLTR
av9oebq 6mpq
28 May 20
Correspondence regarding draft registration statement
12:00am